JPM 2026: Adam Feuerstein’s advice for biotech’s big week

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

My advice for JPM week: chill

Adam Feuerstein/STAT

SAN FRANCISCO — The super-sized gathering of the biopharma universe is important, but it’s not going to make or break the year for biotech. Acquisitions, partnerships, and funding agreements will be hatched during meetings here over the next week. That’s a major reason why thousands of industry people descend on the city and put up with overpriced hotel rooms. 

News flash: All of the stuff that makes biotech go vroom also happens during the 51 remaining weeks of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe